Literature DB >> 1262531

Naproxen plasma levels in volunteers after single-dose administration by oral and rectal routes.

J P Desager, M Vanderbist, C Harvengt.   

Abstract

The bioavailability (plasma concentrations, AUC) of a rectal formulation (suppository) of naproxen was investigated in six healthy volunteers by comparison with an oral preparation (tablets). Plasma half-lives after both formulations were identical 10 hr 15 min+/-25 min (S.D.). Determined by the AUC the bioavailability of naproxen in the suppositories was 94.8%+/-6.3% of the bioavailability of naproxen in the tablets. This paper describes also a new gas-liquid chromatographic method for determining unchanged naproxen in human plasma which is quick, sensitive, and specific.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1262531     DOI: 10.1002/j.1552-4604.1976.tb01516.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  Clinical pharmacokinetics of naproxen.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 3.  Rectal drug administration: clinical pharmacokinetic considerations.

Authors:  A G de Boer; F Moolenaar; L G de Leede; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 4.  Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-10       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.